Hereditary generalized epilepsy

This Phase 3 trial tests a single inhaled dose of alprazolam (a fast-acting sedative) to stop prolonged seizures in people aged 12 and older. The goal is to see if it can end a seizure within 90 seconds and prevent it from coming back for at least 2 hours. About 350 participants …

This early-stage trial tests a gene therapy called RC001 in children aged 2 to 18 with Dravet syndrome, a severe form of epilepsy caused by a genetic mutation. The therapy is given as a single injection into the spinal fluid. The main goal is to check safety and how the body proc…

This study tests a gene therapy called ETX101 for children with Dravet syndrome, a severe form of epilepsy caused by a genetic change. The treatment uses a harmless virus to deliver a working copy of the gene to help control seizures. The trial includes infants and children up to…

This study looks at the long-term safety of the drug brivaracetam in children and teenagers with childhood absence epilepsy or juvenile absence epilepsy. About 120 participants who have already taken the drug in earlier studies will continue treatment and be monitored for side ef…

This study tests whether XEN1101, taken alongside current seizure medications, can reduce the number of generalized tonic-clonic seizures (convulsions affecting the whole body). About 160 people aged 12 and older with these seizures will receive either XEN1101 or a placebo for se…

This study tests whether a modified Atkins diet (low carb, high fat) can control seizures in children aged 3-12 with newly diagnosed absence epilepsy, without using standard medications. Forty children will be enrolled and compared to a group whose parents chose medication instea…

This pilot study tests whether a mild electrical current applied to the scalp (called tDCS) can reduce seizures in people with epilepsy. Thirty adults with hard-to-control epilepsy will use a head device for 30 minutes daily over two months. Researchers will track seizure counts …

This study tests if the drug levetiracetam can prevent epileptic seizures in 120 adults over 40 with Down syndrome and Alzheimer's disease. Participants will receive either the drug or a placebo for 96 weeks. The goal is to see if the drug can stop seizures and possibly slow brai…

This study tests whether an experimental drug called NPT 2042 can reduce the number and length of absence seizures (brief staring spells) in people aged 16-75 with genetic generalized epilepsy. Each participant will receive both the drug and a placebo in random order, with a two-…

This study tracks the safety of Fycompa injection in people with epilepsy who have partial-onset seizures (age 4 and older) or primary generalized tonic-clonic seizures (age 12 and older). Researchers will record any side effects and measure drug levels in children aged 4 to 12. …

This study investigates how rehearsal (repeating information) and sleep help solidify memories in people with epilepsy. Participants learn object-location pairs, with some pairs rehearsed and others not, and their memory is tested after a short delay and again after 12 hours—eith…

This study looks at kidney function in 100 children with epilepsy, aged 1 month to 15 years, at Sohag University Hospital. Researchers will measure blood and urine markers and use ultrasound to check for kidney stones or damage linked to long-term anti-seizure medication. No new …

This study uses powerful MRI scanners to look at the brains and spinal cords of 700 people, including healthy volunteers and those with conditions like multiple sclerosis, Alzheimer's, and Parkinson's. The goal is to understand why some brains stay healthy while others decline. R…

This study aims to find the genetic causes of juvenile myoclonic epilepsy (JME) by collecting blood samples from over 1,000 people with JME across the UK, Europe, and North America. Researchers will compare their DNA to samples from 2,000 healthy controls. The goal is to improve …